Peer Review History
| Original SubmissionOctober 7, 2019 |
|---|
|
PONE-D-19-28016 The 20-year impact of tobacco price and tobacco control expenditure increases in Minnesota, 1998-2017 PLOS ONE Dear Dr. Maciosek, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We would appreciate receiving your revised manuscript by Feb 17 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Stanton A. Glantz Academic Editor PLOS ONE Journal Requirements: 1. When submitting your revision, we need you to address these additional requirements. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating the following in the Financial Disclosure section: [AL, MM and ZX received funding through a research contract between their employer and Clearway Minnesota (http://clearwaymn.org). Coauthors from Clearway Minnesota participated in study design and manuscript preparation.] We note that one or more of the authors are employed by a commercial company: 'Clearway Minnesota'.
Please also include the following statement within your amended Funding Statement. “The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.” If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement. 2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. * Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf. Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests 3. Please include a new copy of Table 1 in your manuscript; the current table is difficult to read. Please follow the link for more information: http://blogs.PLOS.org/everyone/2011/05/10/how-to-check-your-manuscript-image-quality-in-editorial-manager/ Additional Editor Comments (if provided): As you revise the paper, please pay particular attention to the suggestions that would make the results and implications clearer to policy makers. At the same time, including more of the analytical details in the body of the paper can also be accommodated, so long as there are clear statements of the policy implications in the abstract, introduction and discussion highlighted with appropriate subheads. Like most work in this area, the paper concentrates on health cost savings. Reductions in tobacco use also have important cost implications for other sectors of government and society in general. For example, Wendy Max's group has shown that the cost savings to the educational system by reducing AHDH related to secondhand smoke exposure among youth are substantially larger than the direct medical costs (Childhood secondhand smoke exposure and ADHD-attributable costs to the health and education system. Max W, Sung HY, Shi Y. J Sch Health. 2014 Oct;84(10):683-6. doi: 10.1111/josh.12191). There are other issues, such as fires that are also impacted. I am not suggesting that the authors expand the scope of their paper, but they should at least mention these other economic impacts because they are important to policy makers and show that the estimates in their paper are something of a lower bound. The authors need to recognize that their numbers are estimates and report their results rounded to 2 or 3 significant digits, based on the precision of the input variables in the model. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This study assessed the 20-year impact of tobacco price increases and increased tobacco control expenditure during 1998-2017 in Minnesota using a microsimulation model developed by the authors. Different from most of similar studies in the literature, this study include a broader array of outcome: smoking prevalence, disease events, mortality, smoking-attributable medical costs, productivity gains, and state cigarette tax revenues. This a well-written article with details of their models and simulation methodologies presented in the appendices. Although this study made many assumptions about their model parameters, it provided sensitivity analyses to explore the influence of a wide range of changes in model parameters. This study demonstrated that increasing tobacco prices and investments in tobacco control simultaneously is effective to reduce the harms of tobacco use and is cost-saving in the mid- to long-term. I only have several minor comments. 1. Page 7, the methodology of estimating the consequences of cigarette smoking was not explained sufficiently. More description is needed regarding whether and how an econometric model was developed to estimate the smoking-attributable medical costs for current smokers. According to Table S3.1 under the baseline scenario, smoking-attributable medical costs was $1.324 billion in 2017. It would be great if the authors can add some discussion to compare their annual SA medical cost estimates with similar studies in the literature. 2. Page 9, lines 151-153: It is not clear whether the price increases mentioned here ($0.76, $0.67, and $3.10) reflect constant dollar or nominal term. For example, Line 152 indicates that in subsequent years after 1999, the federal excise tax on cigarettes increased by $0.67 per pack. However, during that period, the federal cigarette taxes increased 3 times: by $0.10 per pack in 2000, by $0.05 per pack in 2004, and by $0.61 per pack in 2009. The sum of these increases is $0.76 which does not match to $0.67. 3. Page 9, lines 155-157: “The difference in health … between this ITC + Price Scenario and the ITC scenario provides estimates of the impact of tax increases alone”. This sentence is not correct because this difference also reflects the impact of the price increase due to the Minnesota tobacco lawsuit settlement. 4. Page 11, lines 188-189. The reduced numbers of smokers in 2017 (7,434 for youth and 138,123 for adults) due to ITC do not add up to the number shown in Table S3.4 (146,402). 5. Page 11, lines 201-205; page 12, line 206 and lines 211-203: All the numbers presented in these sentences do no match to the numbers shown in Table 1 and Tables S3.4. 6. Page 12, line 207 and line 215: Add “(data not shown”) after “$784 million”, and similarly after “$3.20 billion”. 7. Page 13, the last row “Base case”: the number shown in the last column does not match to the corresponding cell in Table 1. Reviewer #2: This manuscript presents the findings of a microsimulation to assess the impact of tobacco control policies, including tax increases and increased expenditures on tobacco control, in Minnesota during the twenty year period spanning 1998-2017. The study found that that increased expenditures on tobacco control prevented 37,421 cancer, cardiovascular, diabetes and respiratory disease events and 3,839 deaths over 20 years. Additionally, increased prices prevented an additional 14,702 additional events and 1,662 deaths. The authors conclude that both the net increase in tax revenues and the reduction in medical costs were greater than the additional investments in tobacco control, and that states can pay for initial investments in tobacco control through tax increases and recoup those investments through reduced healthcare expenditures. This manuscript is generally well written, the analytic approach is free from any major methodological pitfalls, and would make a meaningful contribution to the scientific literature. Nonetheless, the manuscript could be improved, including more prominent recognition of various limitations of the analysis. Specific recommendations for revision are as follows: 1. Abstract. Page 2. Introduction. The first sentence of the abstract understates the considerable body of scientific evidence on the efficacy of tobacco control programs; specifically, the language needs to more clearly state the direction of the effect. They don’t just “influence” tobacco use and related health and economic outcomes – they reduce these outcomes. 2. Introduction. Page 4. Third paragraph. The third sentence references “prior initiatives” and “significant policy change during this period.” However, it’s not clear to a lay reader what this means, particularly those without tobacco control expertise. A sentence should be added that clearly articulates what policies were actually implemented. 3. Introduction. Page 4. Since the manuscript only focuses on tobacco control program expenditures and price increases (i.e. and not other specific proven strategies such as smoke-free policies), it would be helpful to better set the stage for inclusion of these variables in the Introduction, including the focus on increased price. One way to accomplish this would be to reinforce that tobacco control expenditures support a variety of efforts, including state and community programs that influence policy adoption, and that increasing price has previously been noted as the single most effective intervention for reducing consumption. That way you better set the stage for the reader around the measures focused upon in the manuscript. 4. Introduction. Page 5. First paragraph. The last two sentences of the Introduction section are implication and discussion points, not Introductory content. They should be deleted here, and reinforced in the Discussion section. 5. Methods. Page 5. Demographics and smoking status. It’s not clear what specific age groups from the “Minnesota population in 1997” the data were adjusted to – was it all individuals, those 18+, or something else? 6. Methods. Page 6. The paragraph beginning “we estimated adult cigarette smoking” lacks necessary precision for the reader to understand the rationale for the employed analytic approach. For example, it’s not clear why 1996 and 1997 data were combined (sample size issue?). Additionally, it’s not clear what is meant by “calibrating the initial smoking probabilities”. Furthermore, it’s not apparent how the 18-24 year old age group, for which there was insufficient sample, could be predicted using estimates for 25-year olds, which reflects only a single age year; did you mean some range that began with 25 as the lower bound? If sample size were an issue, it would seem that you could consider adding multiple years of data to afford sufficient sample for 18-24 year olds, which is a critical smoking initiation demographic. If you can’t this needs to be duly noted as a limitation of the analysis. 7. Methods. Page 7. Consequences of Cigarette Smoking. More clarity needs to be provided in the first paragraph of this section to articulate what smoking-attributable diseases were included. The current framing suggests it could be some, but not all. To clarify, it might be more prudent to place the onus of inclusion on outcomes found to be significantly associated with smoking in the 2014 Surgeon General’s Report, rather than focusing on SAMMEC, which is no longer in existence. 8. Methods. Page 8. It’s unfortunate that the authors could not include smoke-free policies in the analysis, which was undoubtedly a contributor to both declining secondhand smoke exposure, as well as reduced smoking, in Minnesota during the assessed period. This needs to be stated as limitation of the manuscript (along with other proven strategies that couldn’t be included). Additionally, the text in this paragraph of the Methods should use the more commonly recognized term of “secondhand smoke exposure” instead of “secondary smoke exposure”. It’s also not clear what is meant by the statement “the analysis plan was not pre-registered.” 9. Methods. Page 8. It’s strongly recommended that the authors identify another abbreviation than “ITC” for “Increased Investments in Tobacco Control.” The abbreviation “ITC” has long been associated with the International Tobacco Control Survey in the tobacco control field, and thus, using this abbreviation may cause confusion when findings are reported elsewhere or taken out of the direct context of this study. Instead, authors could consider something like Increased Tobacco Control Investments, or “ITCI”. 10. Methods. Page 9. It’s questionable whether it is safe to assume that one policy does not impact the relative effectiveness on smoking behaviors of the other policy. Increased expenditures for tobacco control programs include state and community interventions, as outlined in CDC’s Best Practices for Comprehensive Tobacco Control Programs. Price increases are considered a product of those programs. As such, increased expenditures for programs would be associated with increased momentum around pricing strategies like excise taxes. Since there’s not much else the authors can do post hoc, at the least this should be duly noted as a limitation of the analysis. 11. Discussion. Page 14. It is strongly recommended that the authors not pit individual interventions against one another. The framing around investments being more impactful than price would surely be used by opponents of cigarette excise taxes to state that they aren’t needed because they aren’t as effective. The major take home here is really that both are effective and important as part of a comprehensive approach to tobacco prevention and control at the state level. 12. Discussion. Page 15. The authors appropriately note that tobacco industry marketing efforts could counter the impact of tobacco control investments. However, this point could be made clearer for lay readers if the most recent data from the Federal Trade Commission were cited. In 2017, $9 billion was spent on advertising and promotion of cigarettes— more than $1 million every hour. 13. Discussion. Page 16. The manuscript needs a paragraph that clearly articulates the limitations of the employed analytic approach, including several of the items noted previously in this review (e.g. lack of smoking estimates for 18-24 year olds, omission of full scope of policies such as smoke-free, assumption about independent effect of price and tobacco control program expenditures, etc). 14. Discussion. Another key point to reinforce in the Discussion is that this analysis only accounts for cigarette smoking, not all tobacco products, including other combustible products, smokeless tobacco products, and e-cigarettes. During the later part of the assessed period, particularly from 2011-2017, massive increases in the use of e-cigarettes were observed among youth – both nationally and in Minnesota. Therefore, this model doesn’t account for the full scope of tobacco products being used, as well as associated health risks/costs. Cigarette smoking is certainly responsible for the overwhelming burden of death and disease caused by tobacco use, but these other products are not without risk. Accordingly, this needs to be explicitly stated as a limitation of the analysis, and ideally, a reference to the diversification of the tobacco product landscape should also be made in the narrative elsewhere in the manuscript. 15. Discussion. Another essential point that is briefly referenced, but should be more prominently focused upon, in the manuscript is that a comprehensive approach is warranted. There is no single panacea, and for several decades, tobacco control has most effectively functioned through a comprehensive lens that addresses the various drivers influencing initiation and cessation. As currently framed, the manuscript could be misinterpreted as suggesting that either expenditures and price are effective alone. It’s also important to reinforce that it’s not just making the expenditures, but what those dollars are actually used for; large amounts of dollars allocated to ineffective initiatives or strategies will do little for preventing initiation and reducing consumption at the population level. The expenditures needs to be focused of proven strategies for which evidence of efficacy and cost-effectiveness have been established. Reviewer #3: This is an important paper with findings relevant to continuing policy decisions about the investment of millions of tobacco settlement dollars. The economic analyses are detailed and comprehensive, and provide the basis for important policy discussions and conclusions. As such, the strength and details of these analyses are needed. However, this leads to a key question: what is the primary audience of this paper? The decision appears to be health policy makers, and not health economists. The details in the Supplemental Files are dense but important, and if more were included in the paper it would become more of a health economist paper. However, as written, many of the critical technical details of the model, parameter definitions and selection, sensitivity analysis, and technical aspects of the results are left to the Supplemental Files. Even so, the language of the paper and topics discussed still focus too much on economic issues rather than presenting key findings most relevant to the policy makers. For example, while noted in the discussion that "estimating return on investment for increased ITC was not a study goal..." (lines 290-291), the findings of a positive return on investment even during the limited time horizon is very important, and should not be buried deep in the Discussion. Similarly, the sensitivity analysis is important to these potential return on investment discussions and conclusions, but as presented, these analyses are written more for economists, and as such, will be too confusing to most policy makers. The critical link between the sensitivity analyses and return on investment conclusions needs to be clearly defined when introducing them (line 226). Also, while the Figures (1 and 2) are good at communicating the impact of ITC and Price, the specific data in Table 1 and Supplemental Files S3 are not presented well in the text for policy makers, and especially not summarized well in Abstract. The focus is on deaths and SA incidents averted; however, the bottom line for many policy makers is dollars saved. The medical cost savings and productivity gain estimates are unique to these analyses and should be given primary emphasis, along with the resulting return on investment calculations based upon them. Also, the wealth of literature review, technical discussions, and econometrics in Supplemental Files S1 and S2 are very impressive. As noted above, if the primary audience of the paper is health policy makers, then these details need to stay there. However, the descriptions of the technical approaches in the main paper should be reviewed and considered: are they communicating the technical quality of the work presented in the Supplemental Files to the policy makers as effectively as possible? In many places, the reader should be specifically referred to the excellent presentation of the issues and parameter selection criteria in S1 and S2. More detailed comments: Lines 43-48: I believe this is the only microsimulation model -- and the others, particularly the Levy model is a relatively crude macrosimulation model. This distinction should be emphasized. Lines 59-65: the potential of these findings to provide data needed for cost-effectiveness and return on investment calculations should be introduced and emphasized. Line 70: the details in literature review supporting selection of data inputs, policy parameters, and details in model should get more emphasis here. Lines 128-130: The discussion of clean indoor air legislation should be revised. The specific impact on CIA on health effects of reduced exposures to secondhand smoke are not included (as noted); however, the policy impact of CIA on other outcomes by default are included in the ITC. While these are not specifically included in the model parameters, their impact is captured in the overall results. This should be noted. Lines 131-137: The details of annual tobacco control investments are provided in Supplemental Files. Guide readers to these details. This also could apply to other data included in the model and only shown in detail in Supplemental Files; i.e., annual excise tax levels and average annual retail cigarette prices. Lines 167+: as noted above, the important relevancy of these simulations for explaining return on investment after adjusting for possible biases and reduced parameter estimates for impact of ITC or price, i.e., expenditure and price elasticities, etc. Line 192: "...due to lagged effect of prior investments." will not be understood my almost all readers as being primarily due to two model decisions: first, only one time impact of price increases applied at time of tax increase (standard econometrics) for adults, but impact on youth extended; and second, the use of cumulative funding with 25% discount (a la Farrelly et al models). Maybe this is too technical a point to discuss in results, but might merit being raised in discussion. Line 209: the detailed impacts are shown in S3, but more of them could be shown in an extended Table 1. Additionally, details on annual ITC should be linked with results in S3 to highlight return on investments. Also, S3 could show more details on annual state tax revenues under Baseline Scenario as well as under actual tax increases. Finally, it would be outstanding to see a combined return on investment table combining tax revenues, ITC investments, and SA medical costs. Such a table could have very important policy implications. Table 1: something does not look right. I did not search out all the details in Supplemental Files, but the deaths do not look right. SA cancers (incidents) and SA deaths are almost identical; however, SAMMEC estimates are that only about one-third of SA deaths are due to cancer. This needs to be checked, since SA deaths should be much higher than SA cancer incidents and deaths. Figure 2 (lines 217-224): emphasis on percent changes, but policy impact in $s only shown in Table 1. Figure could be 2a (current) and 2b with numbers (number of youth prevented, increase number of adult quitters, SA incident cases prevented, SA deaths averted, and most importantly, SA costs saved (in $s), productivity gains (in $s) and (to be computed) total savings (SA medical averted and productivity gains). Lines 225-237: as noted above, the impact of sensitivity analyses on return on investment calculations needs more emphasis. Lines 233-236 briefly discuss these findings; but, these calculations need much more emphasis and should be provided in greater detail; maybe even added as additional columns in Table 2. Lines 239-255: this discussion is relevant, but may not strike the right balance. Make it clear from the first sentence that both ITC and price increases are needed: they are complimentary in timing and level of impacts produced. Lines 256-267: discussion of Levy et al model results relevant, but this is a microsimulation model that differs in many ways from their model beyond parameter estimates. Lines 287-296: discussion of uncertainties and imprecisions in model parameters and inputs is always relevant. The details in S1 and S2 provide very good discussion of how parameters and model specifications were done. Point readers to these discussions and reviews. Yes, uncertainties about elasticities, especially about ITC, limit model predictions. Thus, the need for good sensitivity analyses (as was done). Nevertheless, the positive return on investment calculations were found, as well as the positive revenue gains for tax increases (which need more emphasis with more specific numbers provided, even thru this has been documented in many prior econometric analysis). FINALLY, it is suggested that future analyses estimate the even greater impacts (on all outcome measures, but particularly SA cost savings) if ITC levels would have been higher (like full BP levels or even 50% of BP level) or would not have been reduced in 2004. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-19-28016R1 The 20-year impact of tobacco price and tobacco control expenditure increases in Minnesota, 1998-2017 PLOS ONE Dear Dr. Maciosek, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. You have done a nice job of responding to the reviewers. There is only one small change left. In the Introduction, you say that "Large tobacco price increases are the most effective known strategy to reduce tobacco use.” While this is a commonly made statement, as you note elsewhere in the paper, how effective a tax increase is depends on the size of the tax increase. For example, a smokefree law could have a bigger effect than a small tax increase. Please replace "the most effective" with "an effective" and make any other needed wording adjustments to the paper to avoid overstating the importance of tax increases. We would appreciate receiving your revised manuscript by Apr 09 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Stanton A. Glantz Academic Editor PLOS ONE [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
The 20-year impact of tobacco price and tobacco control expenditure increases in Minnesota, 1998-2017 PONE-D-19-28016R2 Dear Dr. Maciosek, We are pleased to inform you that your manuscript has in been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements. Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication. Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. With kind regards, Stanton A. Glantz Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-19-28016R2 The 20-year impact of tobacco price and tobacco control expenditure increases in Minnesota, 1998-2017 Dear Dr. Maciosek: I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. For any other questions or concerns, please email plosone@plos.org. Thank you for submitting your work to PLOS ONE. With kind regards, PLOS ONE Editorial Office Staff on behalf of Professor Stanton A. Glantz Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .